CENTENE CORP

Centene Corporation reported strong second-quarter 2026 financial results, with GAAP diluted EPS of $2.19 and Adjusted diluted EPS of $2.51. The company also raised its full-year 2026 GAAP diluted EPS guidance to greater than $3.11 and Adjusted diluted EPS guidance to greater than $4.80, citing underlying business strength and non-recurring items. Additionally, the company announced a change to its Board of Directors, with Kenneth Burdick resigning and Paul Diaz being appointed as a new director.

Centene reported a strong second quarter 2026, with GAAP net earnings of $1.09 billion, a significant improvement from a loss in the prior year period. Diluted EPS reached $2.19, and total revenues increased to $53.58 billion. The company also highlighted the ongoing divestment of Magellan Health and the sale of $1 billion in Part D receivables.

Centene Corporation announced the appointment of Lauren M. Tyler to its Board of Directors, effective June 19, 2026. The Board increased its size from 9 to 10 members to accommodate the new appointment. Ms. Tyler is anticipated to serve on the Audit Committee and the Compensation and Talent Committee, bringing over 30 years of leadership experience from JPMorgan Chase & Co. and other board roles.

Centene Corp held its Annual Meeting on May 12, 2026, where shareholders elected nine directors for a one-year term and approved the company's executive compensation in a non-binding advisory vote. The appointment of KPMG LLP as the independent auditor for 2026 was also ratified, while a shareholder proposal for an independent board chairman was not approved. Additionally, the company announced the appointments of Daniel Finke as Group President, Medicaid and Marketplace, and Michael Carson as Group President, Medicare and Specialty, solidifying the executive leadership team.

Centene Corp reported Q1 2026 total revenues of $49.94 billion, an increase from $46.62 billion in Q1 2025. GAAP net earnings attributable to Centene rose to $1.54 billion ($3.11 diluted EPS), while adjusted net earnings reached $1.67 billion ($3.37 adjusted diluted EPS). The company also entered a definitive agreement to sell the remaining Magellan Health businesses and sold $1 billion of 2025 Part D risk-sharing program receivables.

Centene Corporation reported strong first-quarter 2026 financial results, with GAAP diluted EPS of $3.11 and adjusted diluted EPS of $3.37, exceeding expectations by approximately $0.50. The company also increased its 2026 adjusted diluted EPS guidance to greater than $3.40, reflecting tangible progress in margin recovery and strengthened operations. Key financial highlights include a 5% increase in premium and service revenues to $44.7 billion, an improved health benefits ratio of 87.3%, and $1.0 billion in debt reduction during the quarter.